Evidence map›Paper›PMID 42118235›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Engineered Carbon Dots from a Traditional Herb Pair Orchestrate Concurrent Antioxidant and AP-1-Mediated Inflammation to Attenuate Renal Ischemia-Reperfusion Injury.

Bixiao Liu, Fuying Zhu, Zhuqing Wang, Jiawen Chen, Xiaomiao Cui, Congzhong Yang, Yao Peng, Dengyuan Feng, Li Lu, Hui Wei and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bixiao LiuDepartment of Andrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Fuying ZhuDepartment of Andrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Zhuqing WangDepartment of Andrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Jiawen ChenDepartment of Biomedical Engineering College of Engineering and Applied Sciences, Nanjing National Laboratory of Microstructures Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing, Jiangsu, China.
Xiaomiao CuiDepartment of Biomedical Engineering College of Engineering and Applied Sciences, Nanjing National Laboratory of Microstructures Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing, Jiangsu, China.
Congzhong YangDepartment of Biomedical Engineering College of Engineering and Applied Sciences, Nanjing National Laboratory of Microstructures Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing, Jiangsu, China.
Yao PengDepartment of Andrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Dengyuan FengDepartment of Andrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0003-0361-7324
Li LuDepartment of Andrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Hui WeiDepartment of Andrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0003-0870-7142
Xiaozhi ZhaoDepartment of Andrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.ORCID https://orcid.org/0009-0007-6339-6355

Funding

Jiangsu Funding Program for Excellent Postdoctoral Talent 2022ZB683National Natural Science Foundation of China 82500836National Natural Science Foundation of China 82570814Natural Science Foundation of Jiangsu Province BK20240244
6 · The paper itself

Abstract

Renal ischemia-reperfusion (I/R) injury, a primary cause of acute kidney injury (AKI), is driven by a self-amplifying loop of oxidative burst and immune cell infiltration. In this work, the classical herb pair Astragalus membranaceus (AM) and Angelica sinensis (AS) is employed as a composite precursor to synthesize nitrogen-rich carbon-dot nanozymes (AM-AS@CDs) via a one-step hydrothermal method. AM‑AS@CDs exhibit superoxide dismutase (SOD)-mimetic activity superior to that of CDs derived from single herbs. In vitro, AM-AS@CDs effectively alleviate oxidative stress-induced cellular damage and significantly inhibit apoptosis. In vivo, AM-AS@CDs markedly attenuate I/R-induced AKI and reduce immune cell infiltration in renal tissues. Transcriptomic analyses reveal that AM-AS@CDs downregulate the expression and phosphorylation of Fosl1 and c-Jun. Consequently, the AP-1-chemokine signaling axis is disrupted, which reduces immune cell recruitment. Furthermore, AM-AS@CDs restore redox homeostasis by upregulating antioxidant enzymes such as SOD, glutathione peroxidase 4 (GPX4), and catalase (CAT). They also attenuate the excessive activation of the Nrf2/HO-1 pathway. Overall, this precursor-formulation strategy enables precise modulation of heteroatom doping and surface chemistry in CDs. AM-AS@CDs effectively interrupt the oxidative-inflammatory positive feedback loop through dual mechanisms. These findings provide both theoretical and material foundations for the development of natural product-based nanozymes for I/R-related diseases.

Indexed as

Acute Kidney InjuryAngelica sinensisAntioxidantsCarbon Quantum DotsInflammationReperfusion InjuryTranscription Factor AP-1AnimalsAstragalus propinquusKidneyMiceOxidative StressAntioxidantsTranscription Factor AP-1acute kidney injuriesastragalus membranaceus and angelica sinensiscarbon dotsimmune cell infiltrationreactive oxygen species

Identifiers

PMID42118235
PMCPMC13336125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.